Article |
Address correspondence to Geoffrey Burnstock, Autonomic Neuroscience Institute, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, U.K. Tel.: 44-20-7830-2948. Fax: 44-20-7830-2949. E-mail: g.burnstock{at}ucl.ac.uk
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key Words: ATP; P2X5; skeletal muscle; differentiation; satellite cells
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
These processes are of key importance in skeletal muscle regeneration. Because skeletal myofibers are terminally differentiated, the regeneration of skeletal muscle is largely dependent on a small population of resident, quiescent cells, termed satellite cells (Perry and Rudnicki, 2000; Seale and Rudnicki, 2000). In response to muscle damage, satellite cells proliferate, become committed to differentiation, exit the cell cycle, and fuse to form multinucleated myotubes. As in muscle development, the MyoD family of basic-helix-loop-helix transcription factors (known as myogenic regulatory factors) is required for the commitment and differentiation of satellite cells during regeneration. This process is also closely tied to cell cycle activity (Lassar et al., 1994; Walsh and Perlman, 1997; Perry and Rudnicki, 2000). Proliferating skeletal satellite cells express high levels of MyoD and Myf5, but on commitment to terminal differentiation these transcription factors are downregulated, and myogenin expression increases. This is followed by activation of the cell cycle arrest protein, p21, and permanent exit from the cell cycle. The differentiation program is then completed with the activation of muscle specific proteins, such as myosin heavy chain (MHC)* and fusion to form multinuclear myotubes (Walsh and Perlman, 1997; Perry and Rudnicki, 2000; Seale and Rudnicki, 2000).
It has long been recognized that the processes of skeletal satellite cell proliferation and differentiation are mutually exclusive (Lassar et al., 1994; Walsh and Perlman, 1997). Understanding the signaling systems involved in directing these cells between proliferation and differentiation is of key importance in developing new therapeutic strategies to treat muscle injury and disease. Many factors, including fibroblast growth factors, insulin-like growth factors, and interleukin-6 cytokines, have already been implicated in the control of satellite cell activity (Hawke and Garry, 2001). In the case of insulin-like growth factors and fibroblast growth factors, the MAPKs have been shown to be involved in mediating these effects (Campbell et al., 1995; Weyman and Wolfman, 1998; Conejo and Lorenzo, 2001; Adi et al., 2002). In particular, extracellular signal-regulated protein kinases (ERKs) 1/2 and p38 MAPK activity has been shown to be involved in directing myogenesis. Whereas a number of studies have demonstrated the importance of the ERK 1/2 pathway in myoblast proliferation (Bennett and Tonks, 1997; Jones et al., 2001), activation of p38 isoforms has been shown to stimulate commitment to differentiation and myotube formation (Chun et al., 2000; Wu et al., 2000; Zetser et al., 1999).
Recent publications demonstrating the expression of ATP receptor subunits (P2X2, P2X5, and P2X6) during skeletal muscle development (Meyer et al., 1999b; Ruppelt et al., 2001; Ryten et al., 2001) suggest that ATP might also act as a trophic factor in skeletal muscle formation. In this paper we used primary cultures of neonatal, rat, skeletal muscle satellite cells to study the role of purinergic signaling in muscle regeneration. We present evidence for the regulated expression of the ionotropic P2X5 receptor protein and mRNA on satellite cells and demonstrate that activation of a P2X receptor inhibits proliferation of satellite cells. Because the processes of myoblast proliferation and differentiation are mutually exclusive (Lassar et al., 1994; Walsh and Perlman, 1997), we also tested the ability of ATP to potentiate differentiation and investigated some of the intracellular mechanisms that might be responsible for mediating these effects.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
The antiproliferative activity of ATP measured at 24 h could not be inhibited by the P2 receptor antagonist reactive blue 2 (RB2) (preapplied for 20 min at 50 µM), but was fully inhibited by pyridoxal 5-phosphate-6-azophenyl-2',4'-disulfonic acid (PPADS) (preapplied for 20 min at 10 µM) (Fig. 2 B). At 72 h, the effect of ATP was only partially inhibited by this antagonist.
Satellite cells express P2X receptors and the expression of P2X5 receptor protein and mRNA is regulated by serum conditions
We investigated the presence of different P2X receptor subunits on satellite cells maintained in growth and differentiating media by using selective antibodies to P2X17. We were unable to detect significant immunoreactivity for any of these receptors in cells maintained in GM. In contrast, cells maintained in DM were strongly immunopositive for the P2X5 receptor subunit only (Fig. 3 A). Using semiquantitative RT-PCR, we were able to demonstrate increased expression of P2X5 receptor mRNA (Fig. 3 B). RT-PCR experiments also provided evidence for the expression of P2X2, P2X4, and P2X6 receptor mRNA (Fig. 3 B). P2X2 receptor mRNA was expressed only at a very low level in cells maintained in DM, whereas P2X4 and P2X6 receptor mRNA was expressed at similar levels in cells maintained under both conditions. Because the only P2X receptors to be differentially expressed were P2X2 and P2X5, this would implicate these receptors in the differential response to ATP of cells maintained in growth or differentiation medium and consequently the antiproliferative effects of ATP.
|
|
|
|
Despite the basal activities of the MAPK pathways, we found that treatment with ATP caused a rapid and significant increase in the levels of phosphorylated p38 and ERK 1/2. Application of 100 µM ATP to cultures maintained in DM caused a significant increase (P < 5%) in p38 phosphorylation at 5 and 10 min (6.9 ± 0.9- and 11.0 ± 1.4-fold increase in p38 phosphorylation at 5 and 10 min, respectively, relative to time zero) (Fig. 6, A and B). Similar but less dramatic changes were also seen with ERK 1/2 phosphorylation. The fold increases in ERK 1/2 were 4.5 ± 1.0 and 6.5 ± 1.8, respectively at 10 min (Fig. 6, A and B). These effects were transient, such that 1 h after application, there was no significant difference in p38 or ERK 1/2 phosphorylation between treated and untreated cultures (Fig. 6 A). After 3 h, cultures treated with ATP had levels of p38 phosphorylation, which were not significantly different from the levels of p38 phosphorylation in untreated cultures after 1 or 24 h (Fig. 6 A).
Inhibition of p38 activity prevented the ATP-dependent reduction in cell proliferation
In order to determine whether the trophic effects of ATP were dependent on activation of MAPK signaling pathways, we used a variety of specific inhibitors of MAPK activity. We found that application of specific inhibitors of MEK1 (responsible for ERK activation), PD95809, and U0126 (Alessi et al., 1995; Favata et al., 1998), resulted in a decrease in cell number (Fig. 7 A). This effect was greater on cells maintained in GM than on cells maintained in DM. At 24 h, U0126 (10 µM) reduced the total number of cells present to 65.16% ± 4.01% of that seen on treated cultures, when cells were maintained in GM, as compared with 88.27% ± 1.64%, when cells were maintained in DM (Fig. 7 A). In contrast, SB203580, the specific inhibitor of p38 and p38ß MAPKs (Lee et al., 1994; Cuenda et al., 1995), had no significant effect on cell number when cells were maintained in either GM or DM (Fig. 7 A).
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Primary rat satellite cells in vitro proliferate, commit to differentiation and fuse to form myotubes in a manner analogous to muscle formation in vivo. This has allowed us to investigate the effects of ATP on skeletal muscle regeneration in an easily accessible and well-characterized system. Using this model, we found that ATP had significant effects on satellite cell activity. Application of 100 µM ATP increased the expression of myogenin and the cell cycle arrest protein p21 at 24 h, and these effects could be blocked using PPADS. Expression of these nuclear proteins has been shown to be necessary for terminal differentiation of myoblasts. Myogenin-null mice, in accordance with the appearance of myogenin at the onset of differentiation, die perinatally due to a severe deficiency of differentiated muscle fibers (Hasty et al., 1993; Nabeshima et al., 1993). As would be expected, upregulation of these transcription factors by ATP: (a) potentiated terminal differentiation of satellite cells, as judged by the expression of MHC and myotube formation; and (b) inhibited satellite cell proliferation. Consistent with evidence that ATP increased expression of p21, we found that the effect of ATP was irreversible. Incubating cells with media containing 100 µM ATP for 1 min, followed by replacement with fresh medium still produced a reduction in cell number.
The antiproliferative effects of ATP at 24 h could not be replicated by application of adenosine, ADP, UTP, or -ß-methylene ATP, and were inhibited by PPADS, but not RB2. However, PPADS is effective at P2Y1 receptors (Schachter et al., 1996, 1997); as ADP (a P2Y1 receptor agonist) had no effect on cell number, this receptor is unlikely to be involved. Therefore, antagonism by PPADS would implicate a P2X receptor (P2X1, P2X2, P2X3, or P2X5) (Lambrecht, 2000). The fact that the P2X1- and P2X3-selective agonist,
-ß-methylene ATP, was found to have no significant effect on cell number, suggests that the receptor involved contained the P2X2 or P2X5 receptor subunits. However, RB2 an antagonist at the P2X2, but not the P2X5, receptor subunit (King et al., 1997; Wildman, S.S., S.G. Brown, M. Rahman, G. Burnstock, J. Urwin, and B.F. King. 2002. Joint Meeting: The Physiological Society, Scandinavian Physiological Society, and Deutsche Physiologische Geselschaft. 81st Annual Meeting. 31 [Abstr.]), could not inhibit the effects of ATP on cell number. Therefore, although we cannot rule out the possibility of a novel, yet to be cloned receptor, this data points strongly to the involvement of the P2X5 receptor.
P2Y receptors are also known to be present in skeletal muscle (Parr et al., 1994; Meyer et al., 1999a; Choi et al., 2001) and the increase in cell number on UTP application could be explained by activation of a P2Y2 or P2Y4 receptor. Because prolonged application of adenosine produced a significant reduction in cell number, which could be inhibited by preapplication of the P1 antagonist, 8-SPT, the presence of a P1 receptor was also demonstrated. However, the effect of ATP applied for 1 min, could only be inhibited by preapplication of PPADS and not 8-SPT. These results suggest that although P1 and P2Y receptors are expressed by satellite cells, a P2X receptor is primarily responsible for the effects of ATP studied in this paper.
The antiproliferative and differentiating effects of ATP could be considered counterintuitive. An obvious, but by no means the only, source of ATP under physiological conditions is damaged myofibers. However, muscle trauma, far from inhibiting satellite cell proliferation, activates quiescent satellite cells to reenter the cell cycle and proliferate. Trauma also results in the release of many other trophic factors, including hepatocyte growth factor and FGFs, known to be capable of promoting satellite cell proliferation (Hawke and Garry, 2001). Therefore, purinoceptor signaling is likely to be only one of many active systems in vivo. Maintenance of cells in high-serum media (GM), when increased levels of trophic factors are likely to be present, could be considered analogous to these conditions. We found that ATP had no effect on cell number even at a concentration of 100 µM, when cells were maintained in GM. Furthermore, under low-serum conditions, ATP not only inhibited cell proliferation, but also potentiated differentiation. This would suggest that the ATP effects studied in this paper relate predominantly to late events in muscle regeneration, when the levels of other trophic factors have fallen and controlled release of ATP from motoneurons (Redman and Silinsky, 1994; Silinsky and Redman, 1996) and muscle activity (Smith, 1991; Cunha and Sebastiao, 1993; Hellsten et al., 1998) can influence satellite cell activity.
One way of varying the response of satellite cells to ATP is to regulate receptor expression. We found that whereas cells maintained in GM expressed no P2X receptor proteins, cells maintained in DM expressed high levels of the P2X5 receptor subunit. Furthermore, maintaining cells in low-serum medium increased the expression of P2X5 receptor mRNA and stimulated the expression of P2X2 receptor mRNA. Because the only P2X receptor to be differentially expressed (on the basis of protein and mRNA) was P2X5, this would implicate this receptor in the differential response of cells maintained in growth or differentiation medium to ATP and consequently the antiproliferative effects of ATP. Certainly the pharmacological profile observed (see above) is consistent with this suggestion.
The mechanism by which P2X5 receptor activation produced effects on satellite cell activity was also investigated. We were able to demonstrate that ATP application to satellite cells produced a significant and rapid increase in the phosphorylation of p38 and, to a lesser extent, ERK 1/2. However, only inhibition of p38 and p38ß activation blocked the P2X-dependent effects on cell number. These results are consistent with previous studies demonstrating the importance of the p38 MAPK signaling pathway in myogenesis. p38 can directly activate the MEF2 transcription factors in skeletal muscle (Zetser et al., 1999; Wu et al., 2000), and together with the MyoD family, MEF2 transcription factors are necessary for the differentiation of myoblasts (Black and Olson, 1998; Molkentin et al., 1995). Thus, overexpression of p38 isoforms or upstream activators stimulate myogenesis, whereas inhibition of p38 activation prevents formation of myotubes (Wu et al., 2000; Zetser et al., 1999).
P2X5 receptor activation results in a rapid and transient flow of cations across the plasma membrane. Thus, like all ionotropic receptors, P2X5 has been viewed as a mediator of transient cellular events. However, recent research on various ligand-gated ion channels, including P2X7 (a member of the P2X receptor family), demonstrates that ionotropic receptors interact with cytoskeletal and signaling proteins (Sheng and Pak, 2000; Kim et al., 2001) and can produce long-term effects on cellular activity. A number of proteins capable of activating intracellular signalling pathways have been shown to interact with the P2X7 receptor, such as phosphatidylinositol 4-kinase (Kim et al., 2001), and it is known that this receptor can activate the p38, ERK 1/2 and JNK MAPK signaling cascades (Humphreys et al., 2000; Panenka et al., 2001). Furthermore, activation of the P2X7 receptor has been shown to produce caspase-dependent apoptosis in various cell types, including microglia, dendritic, and mesangial cells (Schulze-Lohoff et al., 1998; Coutinho Silva et al., 1999; Ferrari et al., 1999). Thus, the results presented in this paper suggest that activation of the P2X5 receptor can produce changes in MAPK signaling pathways by analogous mechanisms.
Although in this paper we have only investigated satellite cells in vitro, recent immunohistochemical and in situ localization studies demonstrate that P2X receptors, notably P2X5, are also expressed during skeletal muscle formation in vivo (Meyer et al, 1999b; Ruppelt et al., 2001; Ryten et al., 2001). P2X2, P2X5, and P2X6 receptor expression have been demonstrated in developing rat and chick skeletal muscle (Meyer et al, 1999b; Ruppelt et al., 2001; Ryten et al., 2001). In chick, P2X5 receptor mRNA and protein was detected not only on myotubes, but also muscle precursor cells in the dermamyotome (Meyer et al., 1999b; Ruppelt et al., 2001). These results suggest that signaling through a P2X receptor containing the P2X5 subunit may be important in muscle formation in vivo, whether in development or regeneration of skeletal muscle. Similarly, immunohistochemical localization of P2X5 in the differentiating cell layers of stratified squamous epithelial tissues suggest a general function for P2X5 receptor-mediated signaling in regulating the balance between cell proliferation and differentiation in a variety of systems.
In summary, we demonstrate in this paper a novel role for ATP in the regulation of skeletal muscle formation. Under differentiating conditions, ATP acts on satellite cells to inhibit proliferation and increase the rate of differentiation. These effects are mediated by upregulation of myogenin and the cell cycle regulator p21. Surprisingly, the effect of ATP is due to the activation of an ionotropic P2X receptor, containing the P2X5 receptor subunit. Although a role for P2X5 in cell differentiation has been proposed, this is the first functional evidence. Thus these results not only open the way for a new therapeutic target in the treatment of myogenic disorders, but also a new role for P2X receptors in the control of cell cycle and fate.
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Electrophysiology
Whole-cell patch clamp recordings were carried out as described previously by Zhong et al. (1998). Agonists were applied rapidly by microperfusion from a four-barrel manifold controlled by computer-driven solenoid valves. Data were acquired using pClamp v8 software (Axon Instruments), and plotted using Origin v4.1 (Microcal). The currentvoltage relationship for the ATP activated current was obtained by subtracting the current response to a ramped change in voltage (-60 to +20 mV, 0.6 s) in the absence of agonist from that recorded in the presence of ATP.
Immunocytochemistry
Skeletal satellite cells were plated on laminin-coated glass coverslips or laminin-coated 8-well LabTek chamberslides (Nunc Life Technologies) for immunocytochemistry. In both cases, cells were fixed for 20 min in 4% paraformaldehyde. After washing in PBS, cells were permeabilized and nonspecific binding sites were blocked using 10% normal goat serum (NGS) + 0.2% Triton X-100 in PBS. Fixed cells were incubated with primary antibodies, diluted in 10% NGS + 0.2% Triton X-100 in PBS, overnight at room temperature. The primary antibodies used were rabbit anti-P2X17 (Roche); rabbit anti-P2Y1, P2Y2, and P2Y4 (Alomone Laboratories); MF20 (University of Iowa Developmental Studies Hybridoma Bank); and rabbit antiskeletal myosin (Sigma-Aldrich). These antibodies were used at the following concentrations: rabbit anti-P2X17, 5 µg/ml; MF20, 1:100 of hybridoma supernatant; and rabbit antiskeletal myosin, 1:100. After washing in PBS, cells were incubated with fluorescence-labeled secondary antibodies for 1 h at 37°C. Donkey antirabbit Cy3 (1:500 in 1% NHS in PBS) or Oregon greenlabelled goat antimouse/rabbit secondary antibodies (Stratech Scientific) (1:100 in 1% NGS in PBS) were applied as appropriate. In some cases, cell nuclei were also stained by incubation with DAPI (Sigma-Aldrich) at 0.6 µg/ml in PBS for 1 h at room temperature. Control experiments were carried out with the primary antibody omitted from the staining procedure and, in the case of the rabbit anti-P2X17 antibodies, the primary antibody preabsorbed with the peptides used to immunize the rabbits.
Drugs used
ATP, ADP, UTP, -ß-meATP (lithium salt), RB2, 8-SPT, and 3,3'-methylene-bis-(4-hydroxy-coumarin) (dicumarol) were purchased from Sigma-Aldrich. PPADS (tetrasodium salt) was supplied by Tocris Cookson Ltd. The kinase inhibitors PD98059, U0126, and SB203580 were purchased from Calbiochem.
Cell counting
Cell number was assessed directly, after trypsin treatment, by staining with trypan blue for viability and counting using a haemocytometer, or indirectly by DNA quantification using the Fluoreporter Blue Fluorometric dsDNA Quantification kit (Molecular Probes).
MHC expression
The number of cells positive for MHC was assessed by first staining cultures with MF20 (see above) and then counting the number of immunoreactive cells in five random fields on three separate coverslips for each treatment.
Myotube assay
Skeletal satellite cells were plated at a density of 5 x 104 cells/cm2 on laminin-coated glass coverslips and maintained in GM overnight. After treatment for 24 h, cells were fixed in 4% paraformaldehyde for 20 min. Myotubes were scored for five random fields on three separate coverslips for each treatment.
Data analysis
Cell/myotube number was expressed as a percentage of that at time zero or as a percentage of the cell/ myotube number in the untreated, control wells after the same time in culture. Each experiment was conducted at least three times with separate preparations of satellite cells. Test and control cultures were run in parallel on each occasion. Differences in cell/myotube number were assessed for significance using a paired, two-tailed Student's t test.
BrdU incorporation assay
Skeletal satellite cells were plated at a density of 1 x 104 cells/cm2 on laminin-coated glass coverslips and maintained in DM overnight. Cells were then treated with ATP and maintained for 12 h, prior to addition of BrdU (at a concentration of 50 µM). After a further 12 h, coverslips were washed with PBS to remove nonadherent cells and the remaining cells fixed with 95% ethanol. Cells were treated with 2 M hydrochloric acid, washed with PBS and incubated with 10% NGS + 0.2% Triton X-100 in PBS for 1 h. The cells were then incubated with mouse anti-Brdu antibody, 1:1,000 in 10% NGS in PBS (Sigma-Aldrich) overnight and staining visualized using Oregon green-labelled goat antimouse secondary antibody (Stratech Scientific). Nuclei were stained using DAPI. The percentage of proliferating cells (nuclei immunopostive for BrdU/nuclei staining for DAPI) was scored for five random fields on three separate coverslips for each treatment.
RT-PCR
Total RNA was extracted from skeletal satellite cells using the SV Total RNA Isolation System (Promega). RT-PCR was performed using Ready-to-Go RT-PCR beads (Amersham Pharmacia Biotech). Reverse transcription was performed using the Moloney murine leukemia virus reverse transcriptase. Primer sequences for P2X17 (Shibuya et al., 1999), p21 (Wong et al., 2000), and myogenin and 16S (Ogilvie et al., 2000) were used for amplification reactions, as reported previously. The amplification reaction, performed in the same reaction tube, was conducted under the following conditions 95°C for 30 s, the relevant annealing temperature for 30 s, and 72°C for 1 min, plus an additional cycle with an elongation time of 5 min. To normalize mRNA levels between samples, PCR reactions were performed for 16 s (ribosomal protein). Amplification products were separated by electrophoresis and visualized by ethidium bromide staining. According to densitometric analysis of the PCR products (BioRad Multi-Imager software), sample loading was adjusted for subsequent PCR reactions for P2X17, p21, and myogenin. The presence of possible contaminants was investigated in all experiments, using control RT-PCR reactions in which, either mRNA had been omitted or the reverse transcriptase had been inactivated by heating to 95°C.
Protein preparation and Western blotting for the MAPK proteins
Skeletal satellite cells were plated at a density of 1 x 104 cells/cm2 on laminin-coated dishes and maintained in DM overnight. Cells were then treated with 100 µM ATP for time periods ranging from 0 min to 24 h. After treatment with ATP, cells were quickly rinsed twice with ice-cold PBS, collected in PBS, and pelleted at 13,000 g for 10 min. Cells were then lysed in a buffer containing 20 mM Tris, pH 7.0, 0.27 M sucrose, 1 mM EDTA, 1 mM EGTA, 50 mM sodium fluoride, 1 mM DTT, 1 mM sodium orthovanadate, 10 mM sodium ß-glycerophosphate, 1% Triton X-100, 1 µg/ml pepstatin A, 4 µM leupeptin, 30 µl/ml aprotinin, and 0.1 mg/ml AEBSF (Calbiochem) for 20 min on ice. The resulting homogenate was centrifuged at 13,000 g for 10 min. The protein concentration was determined using the modified Lowry procedure (Peterson, 1983).
Samples containing equal amounts of protein were subjected to SDS-PAGE using 11% acrylamide and transferred to nitrocellulose filters. Filters were incubated with a blocking solution containing 20 mM Tris, pH 7.7, 137 mM NaCl, 0.1% Tween 20 (TTBS), and 5% nonfat dry milk for 1 h at room temperature, rinsed in TTBS, and then incubated for 1 h at room temperature with specific primary antibodies. The antibodies used were all diluted in 5% bovine serum albumin in TTBS at the following concentrations: rabbit ant-ERK 1/2, 1:5,000 (Cell Signaling Technology); rabbit anti-phospho-ERK 1/2, 1:2,000 (Santa Cruz Biotechnology); rabbit anti-p38, 1:1,000 (Cell Signaling Technology); and mouse antiphospho-p38, 1:1,000 (Cell Signaling Technology). After three rinses in TTBS, filters were incubated for 1 h at room temperature with peroxidase-conjugated antirabbit or antimouse IgG diluted in TTBS (1:20,000 or 1:10,000, respectively) (Amersham Life Sciences). Filters were washed three times in TTBS, and proteins were detected by enhanced chemiluminescence (Amersham Life Sciences). Results were analysed using densitometry (Bio-Rad Multi-Imager software).
![]() |
Footnotes |
---|
![]() |
Acknowledgments |
---|
Submitted: 6 February 2002
Revised: 20 May 2002
Accepted: 20 May 2002
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Adi, S., B. Bin-Abbas, N.Y. Wu, and S.M. Rosenthal. 2002. Early stimulation and late inhibition of extracellular signal-regulated kinase1/2 phosphorylation by IGF-I: a potential mechanism mediating the switch in IGF-I action on skeletal muscle cell differentiation. Endocrinology. 143:511516.
Alessi, D.R., A. Cuenda, P. Cohen, D.T. Dudley, and A.R. Saltiel. 1995. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270:2748927494.
Bennett, A.M., and N.K. Tonks. 1997. Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. Science. 278:12881291.
Burnstock, G. 1997. The past, present and future of purine nucleotides as signalling molecules. Neuropharmacology. 36:11271139.[CrossRef][Medline]
Campbell, J.S., M.P. Wenderoth, S.D. Hauschka, and E.G. Krebs. 1995. Differential activation of mitogen-activated protein kinase in response to basic fibroblast growth factor in skeletal muscle cells. Proc. Natl. Acad. Sci. USA. 92:870874.[Abstract]
Choi, R.C., M.L. Man, K.K. Ling, N.Y. Ip, J. Simon, E.A. Barnard, and K.W. Tsim. 2001. Expression of the P2Y1 nucleotide receptor in chick muscle: its functional role in the regulation of acetylcholinesterase and acetylcholine receptor. J. Neurosci. 21:92249234.
Conejo, R., and M. Lorenzo. 2001. Insulin signaling leading to proliferation, survival, and membrane ruffling in C2C12 myoblasts. J. Cell. Physiol. 187:96108.[CrossRef][Medline]
Coutinho Silva, R., P.M. Persechini, R.D. Bisaggio, J.L. Perfettini, A.C. Neto, J.M. Kanellopoulos, I. Motta Ly, A. Dautry Varsat, and D.M. Ojcius. 1999. P2Z/P2X7 receptor-dependent apoptosis of dendritic cells. Am. J. Physiol. 276:C1139C1147.
Cross, J.V., J.C. Deak, E.A. Rich, Y. Qian, M. Lewis, L.A. Parrott, K. Mochida, D. Gustafson, S. Vande Pol, and D.J. Templeton. 1999. Quinone reductase inhibitors block SAPK/JNK and NFkappaB pathways and potentiate apoptosis. J. Biol. Chem. 274:3115031154.
Cunha, R.A., and A.M. Sebastiao. 1993. Adenosine and adenine nucleotides are independently released from both the nerve terminals and the muscle fibres upon electrical stimulation of the innervated skeletal muscle of the frog. Pflugers Arch. 424:503510.[Medline]
Favata, M.F., K.Y. Horiuchi, E.J. Manos, A.J. Daulerio, D.A. Stradley, W.S. Feeser, D.E. Van Dyk, W.J. Pitts, R.A. Earl, F. Hobbs, et al. 1998. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273:1862318632.
Gröschel-Stewart, U., M. Bardini, T. Robson, and G. Burnstock. 1999. Localisation of P2X5 and P2X7 receptors by immunohistochemistry in rat stratified squamous epithelia. Cell Tissue Res. 296:599605.[CrossRef][Medline]
Hawke, T.J., and D.J. Garry. 2001. Myogenic satellite cells: physiology to molecular biology. J. Appl. Physiol. 91:534551.
Hellsten, Y., D. Maclean, G. Radegran, B. Saltin, and J. Bangsbo. 1998. Adenosine concentrations in the interstitium of resting and contracting human skeletal muscle. Circulation. 98:68.
Humphreys, B.D., J. Rice, S.B. Kertesy, and G.R. Dubyak. 2000. Stress-activated protein kinase/JNK activation and apoptotic induction by the macrophage P2X7 nucleotide receptor. J. Biol. Chem. 275:2679226798.
King, B.F., S.S. Wildman, L.E. Ziganshina, J. Pintor, and G. Burnstock. 1997. Effects of extracellular pH on agonism and antagonism at a recombinant P2X2 receptor. Br. J. Pharmacol. 121:14451453.[Abstract]
Kim, M., L.H. Jiang, H.L. Wilson, R.A. North, and A. Surprenant. 2001. Proteomic and functional evidence for a P2X7 receptor signalling complex. EMBO J. 20:63476358.
Krause, D., A. Lyons, C. Fennelly, and R. O'Connor. 2001. Transient activation of Jun N-terminal kinases and protection from apoptosis by the insulin-like growth factor I receptor can be suppressed by dicumarol. J. Biol. Chem. 276:1924419252.
Lassar, A.B., S.X. Skapek, and B. Novitch. 1994. Regulatory mechanisms that coordinate skeletal muscle differentiation and cell cycle withdrawal. Curr. Opin. Cell Biol. 6:788794.[Medline]
Meyer, M.P., J.D. Clarke, K. Patel, A. Townsend-Nicholson, and G. Burnstock. 1999a. Selective expression of purinoceptor cP2Y1 suggests a role for nucleotide signalling in development of the chick embryo. Dev. Dyn. 214:152158.[CrossRef][Medline]
Molkentin, J.D., B.L. Black, J.F. Martin, and E.N. Olson. 1995. Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins. Cell. 83:11251136.[Medline]
Neary, J.T., M.P. Rathbone, F. Cattabeni, M.P. Abbracchio, and G. Burnstock. 1996. Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Trends Neurosci. 19:1318.[CrossRef][Medline]
Ogilvie, M., X. Yu, V. Nicolas-Metral, S.M. Pulido, C. Liu, U.T. Ruegg, and C.T. Noguchi. 2000. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J. Biol. Chem. 275:3975439761.
Panenka, W., H. Jijon, L.M. Herx, J.N. Armstrong, D. Feighan, T. Wei, V.W. Yong, R.M. Ransohoff, and B.A. MacVicar. 2001. P2X7-like receptor activation in astrocytes increases chemokine monocyte chemoattractant protein-1 expression via mitogen-activated protein kinase. J. Neurosci. 21:71357142.
Parr, C.E., D.M. Sullivan, A.M. Paradiso, E.R. Lazarowski, L.H. Burch, J.C. Olsen, L. Erb, G.A. Weisman, R.C. Boucher, and J.T. Turner. 1994. Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy. Proc. Natl. Acad. Sci. USA. 91:32753279.[Abstract]
Peterson, G.L. 1983. Determination of total protein. Methods Enzymol. 91:95119.[Medline]
Ralevic, V., and G. Burnstock. 1998. Receptors for purines and pyrimidines. Pharmacol. Rev. 50:413492.
Redman, R.S., and E.M. Silinsky. 1994. ATP released together with acetylcholine as the mediator of neuromuscular depression at frog motor nerve endings. J. Physiol. 477:117127.[Abstract]
Ryten, M., A. Hoebertz, and G. Burnstock. 2001. Sequential expression of three receptor subtypes for extracellular ATP in developing rat skeletal muscle. Dev. Dyn. 221:331341.[CrossRef][Medline]
Schachter, J.B., Q. Li, J.L. Boyer, R.A. Nicholas, and T.K. Harden. 1996. Second messenger cascade specificity and pharmacological selectivity of the human P2Y1-purinoceptor. Br. J. Pharmacol. 118:167173.[Abstract]
Schachter, J.B., J.L. Boyer, Q. Li, R.A. Nicholas, and T.K. Harden. 1997. Fidelity in functional coupling of the rat P2Y1 receptor to phospholipase C. Br. J. Pharmacol. 122:10211024.[Abstract]
Seale, P., and M.A. Rudnicki. 2000. A new look at the origin, function, and "stem-cell" status of muscle satellite cells. Dev. Biol. 218:115124.[CrossRef][Medline]
Shibuya, I., K. Tanaka, Y. Hattori, Y. Uezono, N. Harayama, J. Noguchi, Y. Ueta, F. Izumi, and H. Yamashita. 1999. Evidence that multiple P2X purinoceptors are functionally expressed in rat supraoptic neurones. J. Physiol. 514:351367.
Silinsky, E.M., and R.S. Redman. 1996. Synchronous release of ATP and neurotransmitter within milliseconds of a motor nerve impulse in the frog. J. Physiol. 492:815822.[Abstract]
Smith, D.O. 1991. Sources of adenosine released during neuromuscular transmission in the rat. J. Physiol. 432:343354.[Abstract]
Torres, G.E., T.M. Egan, and M.M. Voigt. 1999. Identification of a domain involved in ATP-gated ionotropic receptor subunit assembly. J. Biol. Chem. 274:2235922365.
Weyman, C.M., and A. Wolfman. 1998. Mitogen-activated protein kinase kinase (MEK) activity is required for inhibition of skeletal muscle differentiation by insulin-like growth factor 1 or fibroblast growth factor 2. Endocrinology. 139:17941800.
Wu, Z., P.J. Woodring, K.S. Bhakta, K. Tamura, F. Wen, J.R. Feramisco, M. Karin, J.Y. Wang, and P.L. Puri. 2000. p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Mol. Cell. Biol. 20:39513964.
Zetser, A., E. Gredinger, and E. Bengal. 1999. p38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation. Participation of the Mef2c transcription factor. J. Biol. Chem. 274:51935200.
Zhong, Y., P.M. Dunn, Z. Xiang, X. Bo, and G. Burnstock. 1998. Pharmacological and molecular characterization of P2X receptors in rat pelvic ganglion neurons. Br. J. Pharmacol. 125:771781.[Abstract]